Written by: Jody Agena, PharmD
Understand how to effectively manage adverse effects of Regorafenib treatment in Hepatocellular Carcinoma.
Continue reading Regorafenib in the treatment of Hepatocellular Carcinoma
Authors: Anna Howard, Julia Kerr, Monica McLain, Jessie Modlin
Oral chemotherapy agents are being prescribed more frequently in many cancer types. In-office dispensing of oral chemotherapy agents has demonstrated clinical benefits and also shown financial benefit to third-party payers. A previous publication estimated over $200,000 in cost savings annually from in-office dispensing solely from medications returned to stock for credit. However, pharmacists in the in-office setting perform many other interventions that may affect financial outcomes. Read More.
Oncology Nurse Navigators: Putting the Value in Value-Based Payment Models
Lani M. Alison, BSN, MS-HCQ, PCMH CCE
Oncology nurse navigators provide the “constant” in what seem to be undulating waves of changes to workflows, the adoption of new technology, the near-weekly onslaught of new drugs, and the need to ensure every nuance of documentation is entered in discrete fields in electronic health records so the practice meets reporting requirements. Read More.
PAN New Infographic Spotlight: The Medicare Patient’s Journey—Finding Financial Assistance for Prescription Medications
When a patient is diagnosed with a serious, chronic or life-threatening illness, the costs of treatment can be daunting—especially for those living on fixed incomes.
Our latest infographic illustrates the journey of Mary, a fictional Medicare patient who searches for financial assistance after a metastatic breast cancer diagnosis.
At age 70, Mary lives on a fixed annual income of $26,000 that goes toward necessities like rent, food and other prescriptions. She can’t afford her cancer medication: it has an out-of-pocket cost of $5,000 per year. Learn More.
The purpose of this ASCO Position Statement is to provide a summary of issues our members have raised about the role of PBMs in oncology, to share questions that have surfaced about PBM practices and their impact on physicians and patients, to assert ASCO’s immediate position on key issues, and to highlight areas of concern the Society plans to explore more deeply as part of a focused policy effort.
Read More Here